Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc. Common Stock (AARD) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · AARD · as of Sep 30, 2025
Ownership Breakdown
48
Institutional Holders
▲ 13 vs Q2
$125.74M
Total Inst. Value
▲ $5.20M vs Q2
21.82M
Shares Outstanding
freeFloat 50.01%
9.46M
13F Shares Held
▲ 545,175 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
AARD largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
DECHENG CAPITAL LLC pharmaceutical preparations | 3.92M | 18.06% | 18.06% | $52.06B | Nov 14, 2025 | — held |
CITADEL ADVISORS LLC pharmaceutical preparations | 1.36M | 6.27% | 6.27% | $18.07B | Nov 14, 2025 | ▲ 76.2K |
LAURION CAPITAL MANAGEMENT LP pharmaceutical preparations | 1.05M | 4.84% | 4.84% | $13.95B | Nov 17, 2025 | ▲ 60.7K |
VANGUARD GROUP INC pharmaceutical preparations | 555.7K | 2.56% | 2.56% | $7.39B | Nov 7, 2025 | ▲ 94.7K |
ADAGE CAPITAL PARTNERS GP, L.L.C. pharmaceutical preparations | 350.0K | 1.61% | 1.61% | $4.65B | Nov 14, 2025 | ▲ 175.0K |
MILLENNIUM MANAGEMENT LLC pharmaceutical preparations | 319.6K | 1.47% | 1.47% | $4.25B | Nov 14, 2025 | ▲ 319.6K |
BLACKROCK, INC. pharmaceutical preparations | 309.5K | 1.43% | 1.43% | $4.11B | Nov 12, 2025 | ▲ 103.7K |
SILVERARC CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 306.9K | 1.42% | 1.42% | $4.08B | Nov 12, 2025 | ▲ 20.1K |
SCHONFELD STRATEGIC ADVISORS LLC pharmaceutical preparations | 253.8K | 1.17% | 1.17% | $3.37B | Nov 14, 2025 | ▼ 25.5K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 194.0K | 89.46% | 89.46% | $2.58B | Nov 12, 2025 | ▲ 57.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
22
Increased
+1.16M shares12
New Positions
first time holders7
Decreased
−42.4K shares1
Sold Out
fully exitedNet shares change (top 50)
+1.12M
+1.16M / −42.4K
Net new holders
+26
12 new / 1 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
AARD insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
3
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Sun Nelson Chief Financial Officer | Feb 9, 2026 | Award | 70,549 | $13.48 | $951.0K | 70.5K | Form 4 ↗ |
Jaiman Manasi Chief Medical Officer | Feb 9, 2026 | Award | 70,549 | $13.48 | $951.0K | 70.5K | Form 4 ↗ |
Lee Tien-Li Chief Executive Officer | Feb 9, 2026 | Award | 203,851 | $13.48 | $2.75M | 203.9K | Form 4 ↗ |
Sun Nelson Chief Financial Officer | Dec 11, 2025 | Purchase | 3,000 | $14.40 | $43.2K | 108.5K | Form 4 ↗ |
Lee Tien-Li Chief Executive Officer | Dec 11, 2025 | Purchase | 7,000 | $14.48 | $101.4K | 1.55M | Form 4 ↗ |
Lee Tien-Li Chief Executive Officer | Sep 15, 2025 | Purchase | 3,500 | $9.94 | $34.8K | 1.54M | Form 4 ↗ |
Lee Tien-Li Chief Executive Officer | Sep 15, 2025 | Purchase | 6,500 | $9.51 | $61.8K | 1.54M | Form 4 ↗ |
Lee Tien-Li Chief Executive Officer | Sep 12, 2025 | Purchase | 5,000 | $8.50 | $42.5K | 1.53M | Form 4 ↗ |
Lee Tien-Li Chief Executive Officer | Sep 11, 2025 | Purchase | 6,000 | $7.82 | $46.9K | 1.53M | Form 4 ↗ |
Lee Tien-Li Chief Executive Officer | Sep 10, 2025 | Purchase | 9,000 | $7.91 | $71.2K | 1.52M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Aardvark Therapeutics, Inc. Common Stock (AARD) is primarily owned by institutional investors, who hold approximately 43.4% of total shares outstanding. Company insiders own approximately 49.99%, while retail and public investors account for the remaining 6.64%.
The largest institutional shareholder of Aardvark Therapeutics, Inc. Common Stock is DECHENG CAPITAL LLC, holding approximately 3.92 million shares — equal to 18.06% of outstanding shares — as of September 30, 2025.
A total of 48 institutional investors currently hold AARD stock, with a combined institutional value of approximately $125,736,962 as of the most recent 13F filing period.
Frequently asked questions
AARD ownershipAardvark Therapeutics, Inc. Common Stock (AARD) is primarily owned by institutional investors, who hold approximately 43.4% of shares. The largest shareholder is DECHENG CAPITAL LLC with a 18.06% stake. Company insiders hold 49.99%. Data sourced from SEC Form 13F as of September 30, 2025.